Brain Advance Access originally published online on June 23, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 127, No. 8, 1831-1844,
August 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh203
Clinical analysis of anti-Ma2-associated encephalitis
1 Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA, 2 Service of Neurology and Institut d'Investigacions Biomèdiques August Pí i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Spain, 3 Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY, 4 Departments of Neurology, Neurosurgery, and Oncology, University of Utah School of Medicine/Huntsman Cancer Institute, UT, USA and 5 Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
Correspondence to: Josep Dalmau, MD, PhD, Department of Neurology, 3 W. Gates, Division of Neuro-oncology, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA E-mail: jdalmau{at}mail.med.upenn.edu
Increasing experience indicates that anti-Ma2-associated encephalitis differs from classical paraneoplastic limbic or brainstem encephalitis, and therefore may be unrecognized. To facilitate its diagnosis we report a comprehensive clinical analysis of 38 patients with anti-Ma2 encephalitis. Thirty-four (89%) patients presented with isolated or combined limbic, diencephalic or brainstem dysfunction, and four with other syndromes. Considering the clinical and MRI follow-up, 95% of the patients developed limbic, diencephalic or brainstem encephalopathy. Only 26% had classical limbic encephalitis. Excessive daytime sleepiness affected 32% of the patients, sometimes with narcolepsy-cataplexy and low CSF hypocretin. Additional hormonal or MRI abnormalities indicated diencephalic-hypothalamic involvement in 34% of the patients. Eye movement abnormalities were prominent in 92% of the patients with brainstem dysfunction, but those with additional limbic or diencephalic deficits were most affected; 60% of these patients had vertical gaze paresis that sometimes evolved to total external ophthalmoplegia. Three patients developed atypical parkinsonism, and two a severe hypokinetic syndrome with a tendency to eye closure and dramatic reduction of verbal output. Neurological symptoms preceded the tumour diagnosis in 62% of the patients. Brain MRI abnormalities were present in 74% of all patients and 89% of those with limbic or diencephalic dysfunction. Among the 34 patients with cancer, 53% had testicular germ-cell tumours. Two patients without evidence of cancer had testicular microcalcification and one cryptorchidism, risk factors for testicular germ-cell tumours. After neurological syndrome development, 17 of 33 patients received oncological treatment (nine also immunotherapy), 10 immunotherapy alone, and six no treatment. Overall, 33% of the patients had neurological improvement, three with complete recovery; 21% had long-term stabilization, and 46% deteriorated. Features significantly associated with improvement or stabilization included, male gender, age <45 years, testicular tumour with complete response to treatment, absence of anti-Ma1 antibodies and limited CNS involvement. Immunosuppression was not found to be associated with improvement but was clearly effective in some patients. Fifteen patients (10 women, five men) had additional antibodies to Ma1. These patients were more likely to have tumours other than testicular cancer and to develop ataxia, and had a worse prognosis than patients with only anti-Ma2 antibodies (two women, 21 men); 67% of deceased patients had anti-Ma1 antibodies. Anti-Ma2 encephalitis (with or without anti-Ma1 antibodies) should be suspected in patients with limbic, diencephalic or brainstem dysfunction, MRI abnormalities in these regions, and inflammatory changes in the CSF. In young male patients, the primary tumour is usually in the testis, in other patients the leading neoplasm is lung cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Tenner and L. Einhorn Ma-2 Paraneoplastic Encephalitis in the Presence of Bilateral Testicular Cancer: Diagnostic and Therapeutic Approach J. Clin. Oncol., August 10, 2009; 27(23): e57 - e58. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cho, Y. Lim, and J. A. Golden SUMO Interaction Motifs in Sizn1 Are Required for Promyelocytic Leukemia Protein Nuclear Body Localization and for Transcriptional Activation J. Biol. Chem., July 17, 2009; 284(29): 19592 - 19600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Saiz, J Bruna, P Stourac, M C Vigliani, B Giometto, W Grisold, J Honnorat, D Psimaras, R Voltz, and F Graus Anti-Hu-associated brainstem encephalitis J. Neurol. Neurosurg. Psychiatry, April 1, 2009; 80(4): 404 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Foster and J. P. Caplan Paraneoplastic Limbic Encephalitis Psychosomatics, March 1, 2009; 50(2): 108 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wagner, C. Schankin, T. Birnbaum, G. Popperl, and A. Straube OCULAR MOTOR AND LID APRAXIA AS INITIAL SYMPTOM OF ANTI-Ma1/Ma2-ASSOCIATED ENCEPHALITIS Neurology, February 3, 2009; 72(5): 466 - 467. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Daffner, J. C. Sherman, R. G. Gonzalez, and R. P. Hasserjian Case 35-2008 -- A 65-Year-Old Man with Confusion and Memory Loss N. Engl. J. Med., November 13, 2008; 359(20): 2155 - 2164. [Full Text] [PDF]
|
|
|
|
|
|
A Eker, E Saka, J Dalmau, A Kurne, C Bilen, H Ozen, D Ertoy, K K Oguz, and B Elibol Testicular teratoma and anti-N-methyl-D-aspartate receptor-associated encephalitis J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1082 - 1083. [Full Text] [PDF]
|
|
|
|
|
|
L A Hoffmann, S Jarius, H L Pellkofer, M Schueller, M Krumbholz, F Koenig, W Johannis, C la Fougere, T Newman, A Vincent, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases J. Neurol. Neurosurg. Psychiatry, July 1, 2008; 79(7): 767 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Pruss, R. Zschenderlein, K. Prass, J. Dalmau, and R. M. Mathew ORCHIECTOMY FOR SUSPECTED MICROSCOPIC TUMOR IN PATIENTS WITH ANTI-MA2-ASSOCIATED ENCEPHALITIS Neurology, August 14, 2007; 69(7): 709 - 710. [Full Text] [PDF]
|
|
|
|
|
|
H. Pruss, R. Voltz, B. Flath, B. Rudolph, R. Klingebiel, R. Zschenderlein, and K. Prass Anti-Ta-associated paraneoplastic encephalitis with occult testicular intratubular germ-cell neoplasia J. Neurol. Neurosurg. Psychiatry, June 1, 2007; 78(6): 651 - 652. [Full Text] [PDF]
|
|
|
|
|
|
L Bataller, K A Kleopa, G F Wu, J E Rossi, M R Rosenfeld, and J Dalmau Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 381 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S R Samarasekera, A Vincent, J L Welch, M Jackson, P Nichols, and T D Griffiths Course and outcome of acute limbic encephalitis with negative voltage-gated potassium channel antibodies J. Neurol. Neurosurg. Psychiatry, April 1, 2007; 78(4): 391 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Mathew, R. Vandenberghe, A. Garcia-Merino, T. Yamamoto, J. C. Landolfi, M. R. Rosenfeld, J. E. Rossi, B. Thiessen, E. J. Dropcho, and J. Dalmau Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis Neurology, March 20, 2007; 68(12): 900 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Rojas-Marcos, F. Graus, G. Sanz, A. Robledo, and C. Diaz-Espejo Hypersomnia as presenting symptom of anti-Ma2-associated encephalitis: Case study Neuro-oncol, January 1, 2007; 9(1): 75 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Blumenthal, K. L. Salzman, K. B. Digre, R. L. Jensen, W. A. Dunson, and J. Dalmau Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis. Neurology, July 11, 2006; 67(1): 146 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Schott Limbic encephalitis: a clinician's guide Practical Neurology, June 1, 2006; 6(3): 143 - 153. [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. de Beukelaar and P. A. S. Smitt Managing paraneoplastic neurological disorders. Oncologist, March 1, 2006; 11(3): 292 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Waragai, A Chiba, A Uchibori, T Fukushima, M Anno, and K Tanaka Anti-Ma2 associated paraneoplastic neurological syndrome presenting as encephalitis and progressive muscular atrophy J. Neurol. Neurosurg. Psychiatry, January 1, 2006; 77(1): 111 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Ances, R. Vitaliani, R. A. Taylor, D. S. Liebeskind, A. Voloschin, D. J. Houghton, S. L. Galetta, M. Dichter, A. Alavi, M. R. Rosenfeld, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates Brain, August 1, 2005; 128(8): 1764 - 1777. [Abstract] [Full Text] [PDF]
|
|